Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$11.22 CAD
Change Today -0.20 / -1.75%
Volume 121.0
NVC On Other Exchanges
As of 3:59 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

neovasc inc (NVC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - C$12.75
52 Week Low
08/26/14 - C$4.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOVASC INC (NVC)

Related News

No related news articles were found.

neovasc inc (NVC) Related Businessweek News

No Related Businessweek News Found

neovasc inc (NVC) Details

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Neovasc Reducer for the treatment of refractory angina; and Tiara technology in development for the transcatheter treatment of mitral valve disease. The company also develops and manufactures the PeriPatch, a line of biological tissue products for use in third-party medical products, including transcatheter heart valves. In addition, the company provides a range of custom Peripatch products to industry customers for incorporation into their own products; and consulting and original equipment manufacturing services to other medical device companies. Further, it offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

119 Employees
Last Reported Date: 05/13/14
Founded in 2000

neovasc inc (NVC) Top Compensated Officers

Chief Executive Officer and Non-Independent D...
Total Annual Compensation: C$302.5K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$242.0K
Chief Operating Officer and President of Neov...
Total Annual Compensation: C$192.5K
Vice President of Research and Development
Total Annual Compensation: C$174.9K
Compensation as of Fiscal Year 2013.

neovasc inc (NVC) Key Developments

Neovasc Inc. Launches Reducer in Select European Countries

Neovasc Inc. announced the Neovasc Reducer has been introduced to select centers in Italy and will shortly be available for routine use at additional sites in Germany, the UK and Switzerland. The first two Italian cases were performed by Dr. Antonio Colombo, Director, Cardiac Cath Lab and Interventional Cardiology Unit, EMO GVM Centro Cuore, Columbus and San Raffaele Hospital, Milan, Italy. The Reducer treats refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms. The Reducer alters blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that can be completed in approximately 30 minutes.

Neovasc Inc. Announces the Final Results from its COSIRA Study

Neovasc Inc. announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina. Refractory Angina is a debilitating disease involving chronic chest pain and affecting millions of patients worldwide who have limited treatment options. The COSIRA study met its primary endpoint, demonstrating the efficacy of the Reducer in relieving angina symptoms in these patients. The Canadian Cardiovascular Society ("CCS") angina grading scale is a four-class functional classification that is widely used to characterize the severity of angina symptoms and disability. Only patients with severe angina, CCS Class 3 or 4, were enrolled in the COSIRA trial. The COSIRA data demonstrates that patients treated with the Reducer achieved a statistically significant improvement in CCS angina grading scale scores (two classes or better) compared to those patients in the sham control arm, (p-value = 0.024). Patients treated with the Reducer were 2.3 times more likely to see an improvement of two classes or better in CCS score than the sham control arm. The analysis also demonstrated that patients treated with the Reducer showed a statistically significant improvement of one or more CCS classes compared to the sham control patients (p-value = 0.003). The study also demonstrated a 96.2% technical success rate and a 100% procedural success rate for Reducer implantation.

Neovasc Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 10:40 AM

Neovasc Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 10:40 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Alexei J. Marko, Chief Executive Officer and Non-Independent Director, Chris Clark, Chief Financial Officer and Corporate Secretary.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVC:CN C$11.22 CAD -0.20

NVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $141.90 USD -0.35
St Jude Medical Inc $65.28 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation NVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.7x
Price/Book 21.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVASC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at